The virus carrying the mutation from South Africa was produced
ANTIBODY RATIO FALLS TO TWO THREE
Scientists have noted that the antibody rate has dropped to two-thirds when the virus produced against the S. Africa mutation is compared to the common type of the mutated virus in the USA. It is not known whether a two-thirds reduction in antibody level will render the vaccine ineffective against this variant, since there is no limit to what extent the antibody provides protection against the virus so far. Pei-Yong Shi, an expert at the University of Texas, who made a statement about the research, noted that the BionTech / Pfizer vaccine is also possible to protect against the variant. “I can say that the immune response created by the vaccine is far above the level required to provide protection.”
VARIANT IN SOUTH AFRICA WAS DETERMINED IN 31 COUNTRIES